Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1 + migratory dendritic cell axis in breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
10.1038/s41467-019-08593-4 · 2019 · External reference
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
10.1172/jci176454 · 2024 · External reference
10.1016/j.cell.2018.03.041
10.1016/j.cell.2018.03.041 · External reference
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
10.1016/j.esmoop.2024.103619 · 2024 · External reference
Tertiary lymphoid structures in cancer
10.1126/science.abf9419 · 2022 · External reference
10.1038/s41568-019-0144-6
10.1038/s41568-019-0144-6 · External reference
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
10.1038/s43018-021-00232-6 · 2021 · External reference
Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis
10.1016/j.intimp.2024.112790 · 2024 · External reference
10.1016/j.ajpath.2011.03.007
10.1016/j.ajpath.2011.03.007 · External reference
Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
10.3390/ijms232314937 · 2022 · External reference
Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer
10.1002/cam4.5788 · 2023 · External reference
10.1158/2159-8290.cd-20-1557
10.1158/2159-8290.cd-20-1557 · External reference
Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies
10.1016/j.semcancer.2021.07.010 · 2022 · External reference
Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets
10.1126/sciadv.adf0837 · 2023 · External reference
10.1038/nrclinonc.2015.73
10.1038/nrclinonc.2015.73 · External reference
Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer Using Preoperative MRI-Based Radiomics
10.1002/jmri.27910 · 2022 · External reference
Radiomics Model for Evaluating the Level of Tumor-Infiltrating Lymphocytes in Breast Cancer Based on Dynamic Contrast-Enhanced MRI
10.1016/j.clbc.2020.12.008 · 2021 · External reference
Radiomic models based on magnetic resonance imaging predict the spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer
10.3389/fimmu.2022.1080048 · 2022 · External reference
Habitat Imaging With Tumoral and Peritumoral Radiomics for Prediction of Lung Adenocarcinoma Invasiveness on Preoperative Chest CT: A Multicenter Study
10.2214/ajr.24.31675 · 2024 · External reference
10.1148/radiol.2015151169
10.1148/radiol.2015151169 · External reference
Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer
10.1038/s41698-025-01012-6 · 2025 · External reference
10.3322/caac.21388
10.3322/caac.21388 · External reference
10.1109/tmi.2010.2046908
10.1109/tmi.2010.2046908 · External reference
10.1109/42.836373
10.1109/42.836373 · External reference
Evolutionary Multiobjective Clustering and Its Applications to Patient Stratification
10.1109/tcyb.2018.2817480 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1016/j.cmpb.2021.106584
10.1016/j.cmpb.2021.106584 · External reference
10.1016/j.ccell.2022.05.005
10.1016/j.ccell.2022.05.005 · External reference
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
10.1186/gb-2006-7-10-r100 · 2006 · External reference
Quantification of histochemical staining by color deconvolution
2001 · External reference
10.1158/1055-9965.epi-18-0863
10.1158/1055-9965.epi-18-0863 · External reference
10.1186/bcr1325
10.1186/bcr1325 · External reference
10.1007/s10549-010-0897-9
10.1007/s10549-010-0897-9 · External reference
10.1001/jama.2011.593
10.1001/jama.2011.593 · External reference
10.1016/j.ccell.2023.12.012
10.1016/j.ccell.2023.12.012 · External reference
10.1016/j.cell.2021.04.048
10.1016/j.cell.2021.04.048 · External reference
10.1016/j.cell.2019.05.031
10.1016/j.cell.2019.05.031 · External reference
The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures
10.3389/fimmu.2021.694079 · 2021 · External reference
10.1038/s41416-019-0664-6
10.1038/s41416-019-0664-6 · External reference
10.1158/1078-0432.ccr-18-2882
10.1158/1078-0432.ccr-18-2882 · External reference
Recent update on the discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy
10.1016/j.ejmech.2025.118017 · 2025 · External reference
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive “Cold” Tumors “Hot”
10.1016/j.trecan.2017.11.005 · 2018 · External reference
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
10.1016/j.xcrm.2024.101799 · 2024 · External reference
10.1038/s41591-018-0014-x
10.1038/s41591-018-0014-x · External reference
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
10.1186/s40425-019-0768-9 · 2019 · External reference
10.1056/nejmoa1910549
10.1056/nejmoa1910549 · External reference
10.1038/s41591-024-03415-7
10.1038/s41591-024-03415-7 · External reference
10.1038/s41379-020-0544-x
10.1038/s41379-020-0544-x · External reference
10.1093/jnci/djab108
10.1093/jnci/djab108 · External reference
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
10.1038/s41392-024-01947-5 · 2024 · External reference
10.1007/s00262-019-02407-8
10.1007/s00262-019-02407-8 · External reference
Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis
10.1186/s12935-021-02242-x · 2021 · External reference
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
10.1186/s40164-024-00543-1 · 2024 · External reference
10.1016/j.ccell.2024.06.014
10.1016/j.ccell.2024.06.014 · External reference
10.1038/s12276-023-01028-7
10.1038/s12276-023-01028-7 · External reference
10.1038/cmi.2017.143
10.1038/cmi.2017.143 · External reference
10.1038/nri1457
10.1038/nri1457 · External reference
10.1016/s1470-2045(19)30274-8
10.1016/s1470-2045(19)30274-8 · External reference
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial
10.1001/jamaoncol.2020.5572 · 2021 · External reference
10.1093/nar/gkae973
10.1093/nar/gkae973 · External reference
